Medical School of Chinese PLA Beijing China.
Senior Department of Neurosurgery The First Medical Center of Chinese PLA General Hospital Beijing China.
J Am Heart Assoc. 2024 Aug 6;13(15):e034707. doi: 10.1161/JAHA.124.034707. Epub 2024 Jul 18.
This study investigated the long-term clinical and angiographic outcomes of encephaloduroarteriosynangiosis treatment for symptomatic intracranial atherosclerotic arterial steno-occlusive disease to further evaluate the potential therapeutic role of encephaloduroarteriosynangiosis in this population.
A total of 152 adult patients with symptomatic intracranial atherosclerotic arterial steno-occlusive disease who were treated with encephaloduroarteriosynangiosis and intensive medical management across 3 tertiary centers in China between January 2011 and September 2019 were retrospectively included. The primary outcomes were defined as postoperative cerebrovascular events, including ischemic and hemorrhagic stroke. The postoperative neovascularization was analyzed qualitatively and quantitatively by using angiography. Clinical, radiological, and long-term follow-up data were analyzed using Cox regression, logistic regression, and linear regression analyses. Primary outcome rates were 3.2% (5/152) within 30 days, 6.6% (10/152) within 2 years, 9.2% (14/152) within 5 years, and 11.1% (17/152) during a median 9.13 years follow-up. Initial infarction symptoms were positively associated with recurrent ischemic stroke. Additionally, posterior circulation involvement and coexisting cardiac disease indicated poorer neurological status, whereas encephaloduroarteriosynangiosis neovascularization efficacy was negatively associated with older age and vascular risk factors but positively associated with posterior circulation involvement.
Encephaloduroarteriosynangiosis plus intensive medical management appears efficacious and safe for symptomatic intracranial atherosclerotic arterial steno-occlusive disease, with low perioperative risk and favorable long-term results. Further prospective trials are needed to verify its efficacy and determine the optimal patient selection criteria.
本研究旨在探讨硬脑膜-动脉血管融通术治疗症状性颅内动脉粥样硬化性狭窄闭塞性疾病的长期临床和血管造影结果,以进一步评估硬脑膜-动脉血管融通术在该人群中的潜在治疗作用。
回顾性纳入了 2011 年 1 月至 2019 年 9 月期间在中国 3 家三级中心接受硬脑膜-动脉血管融通术和强化药物治疗的 152 例症状性颅内动脉粥样硬化性狭窄闭塞性疾病的成年患者。主要结局定义为术后脑血管事件,包括缺血性卒中和出血性卒中。通过血管造影术对术后新生血管进行定性和定量分析。采用 Cox 回归、Logistic 回归和线性回归分析对临床、影像学和长期随访数据进行分析。30 天内主要结局发生率为 3.2%(5/152),2 年内为 6.6%(10/152),5 年内为 9.2%(14/152),中位随访 9.13 年内为 11.1%(17/152)。初始梗死症状与复发性缺血性卒中呈正相关。此外,后循环受累和并存的心脏疾病提示神经功能状态较差,而硬脑膜-动脉血管融通术新生血管化疗效与年龄较大和血管危险因素呈负相关,但与后循环受累呈正相关。
硬脑膜-动脉血管融通术联合强化药物治疗对症状性颅内动脉粥样硬化性狭窄闭塞性疾病有效且安全,围手术期风险低,长期效果良好。需要进一步的前瞻性试验来验证其疗效,并确定最佳的患者选择标准。